Article | October 19, 2023

3 Key Takeaways Of Annex 1: What It Means For Your Cold Chain Management

Source: Sartorius
Compliance GettyImages-1212446127

The latest update to Annex 1 clarifies and expands upon EMA guidelines for the manufacture of sterile medicinal products. Given that regulatory and manufacturing environments have changed dramatically since the last revision in 2007, the new guidelines are much needed and largely welcomed within the pharmaceutical industry.

Harmful contamination can occur at virtually any stage of drug product processing, storage, and transport. Consequently, the updated guidelines emphasize that manufacturers must integrate an effective risk management system into all aspects of the bulk drug product lifecycle.

What are the practical implications of all this, specifically for cold chain management? Sartorius asked a few in-house experts for their thoughts on the subject.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online